Polymorphs and salts of a kinase inhibitor

摘要

The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARP).

主权项

1. A crystalline polymorph of a salt of compound (I):characterized by having powder X-ray diffraction pattern peaks of 2θ at about:
(a) 26.2°, and 27.2°, the salt being sodium salt Form II; or (b) 25.9°, 27.1° and 27.9°, the salt being sodium salt Form III; or (c) 22.8°, and 25.3°, the salt being sodium salt Form IV; or (d) 12.3° and 31.3°, the salt being sodium salt Form V; or (e) 20.7° and 26.0°, the salt being sodium salt Form VI; or (f) 12.2° and 17.7°, the salt being sodium salt Form VII; or (g) 24.4° and 25.4°, the salt being sodium salt Form VIII; or (h) 15.8° and 16.5°, the salt being sodium salt Form IX; or (i) 23.6° and 28.4°, the salt being sodium salt Form X; or (j) 24.4°, 24.9° and 26.4°, the salt being sodium salt Form XI; or (k) 26.3° and 30.7°, the salt being sodium salt Form XII.